Figure 7.

(A) In vivo tCho density maps from 2D CSI datasets acquired from arepresentative PC3-PIPtumor (~400 mm³) before and 48 h after i.v. injection of the PSMA-targeted nanoplex 1 (150 mg/kg). Parameters used were TE = 120 ms, TR= 1000 ms, 4 scans per phase encode step. CSI spectra were acquired at 9.4 T with an in-plane spatial resolution of 1 mm × 1 mm from a 4 mm thick slice. (B) Corresponding in vivo tCho maps from the same 2D CSI data sets. (C) Representative one voxel spectra from 2D CSI represented in A and B. (D) tCho concentration calculated in arbitrary units before and at 48 h after injection of nanoplex 1. Values represent median ± SEM (n = 3, *P < 0.05). (E) In vivo ¹⁹FMR spectra acquired from a PC3-PIP tumor (~400 mm³) at 24 and 48 h after i.v. injection of the PSMA-targeted nanoplex (150 mg/kg) carrying bCD and siRNA-Chk. Spectra were acquired after a combined i.v. and i.p. injection of 5-FC (450 mg/kg) on a Bruker Biospec 9.4 T spectrometer using a 1 cm solenoid coil tunable to ¹H and ¹⁹F frequency. Following shimming on the water proton signal, serial nonselective ¹⁹F MR spectra were acquired starting 20 min after the 5-FC injection and continued every 30 min for 110 min with a repetition time of 0.8 s, a number of scans of 2000, and a spectral width of 10 kHz.